SENORESPharmaceuticals
Senores Pharmaceuticals Ltd — Cash Flow Statement
₹759.60
+0.92%
Senores Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Free Cash Flow | -203.44 Cr | -77.53 Cr | -48.36 Cr | -21.13 Cr |
| Issuance Of Capital Stock | 471.76 Cr | 36.99 Cr | 2.68 Cr | 24.02 Cr |
| Capital Expenditure | -157.52 Cr | -51.83 Cr | -47.28 Cr | -10.68 Cr |
| End Cash Position | 105.38 Cr | 7.64 Cr | 0.10 Cr | 3.21 Cr |
| Other Cash Adjustment Outside Changein Cash | 0.01 Cr | 0.49 Cr | — | — |
| Beginning Cash Position | 7.65 Cr | 0.10 Cr | 3.21 Cr | 1.64 Cr |
| Changes In Cash | 97.72 Cr | 7.05 Cr | -3.12 Cr | 1.57 Cr |
| Financing Cash Flow | 573.13 Cr | 86.98 Cr | 46.25 Cr | 36.46 Cr |
| Net Other Financing Charges | -0.01 Cr | -1.35 Cr | -1.18 Cr | 2.54 Cr |
| Interest Paid Cff | -20.36 Cr | -8.50 Cr | -1.84 Cr | -0.51 Cr |
| Net Common Stock Issuance | 471.76 Cr | 36.99 Cr | 2.68 Cr | 24.02 Cr |
| Common Stock Issuance | 471.76 Cr | 36.99 Cr | 2.68 Cr | 24.02 Cr |
| Net Issuance Payments Of Debt | 121.01 Cr | 61.21 Cr | 46.55 Cr | 10.50 Cr |
| Net Short Term Debt Issuance | 92.20 Cr | 58.04 Cr | 29.04 Cr | 1.51 Cr |
| Net Long Term Debt Issuance | 28.81 Cr | 3.17 Cr | 17.52 Cr | 8.99 Cr |
| Investing Cash Flow | -429.49 Cr | -54.23 Cr | -48.29 Cr | -24.44 Cr |
| Net Other Investing Changes | -0.01 Cr | 0.01 Cr | — | 10000.00 |
| Interest Received Cfi | 7.16 Cr | 0.46 Cr | 0.04 Cr | 0.19 Cr |
| Net Investment Purchase And Sale | -275.76 Cr | 0.00 | — | — |
| Net Business Purchase And Sale | -3.69 Cr | -3.29 Cr | -1.05 Cr | -13.95 Cr |
| Purchase Of Business | -3.69 Cr | -3.29 Cr | -1.05 Cr | -13.95 Cr |
| Net PPE Purchase And Sale | -157.52 Cr | -51.83 Cr | -47.28 Cr | -10.68 Cr |
| Purchase Of PPE | -157.52 Cr | -51.83 Cr | -47.28 Cr | -10.68 Cr |
| Operating Cash Flow | -45.92 Cr | -25.70 Cr | -1.08 Cr | -10.45 Cr |
| Taxes Refund Paid | -9.17 Cr | -2.49 Cr | -1.45 Cr | -0.14 Cr |
| Change In Working Capital | -134.43 Cr | -66.05 Cr | -14.61 Cr | -12.53 Cr |
| Change In Other Current Liabilities | 3.72 Cr | 1.16 Cr | 4.87 Cr | -1.11 Cr |
| Change In Other Current Assets | -63.53 Cr | -60.60 Cr | -25.99 Cr | -0.66 Cr |
| Change In Payable | -45.79 Cr | 50.90 Cr | 6.45 Cr | 7.01 Cr |
| Change In Inventory | -19.26 Cr | -1.04 Cr | -0.14 Cr | -2.64 Cr |
| Change In Receivables | -11.88 Cr | -57.11 Cr | -1.54 Cr | -15.21 Cr |
| Other Non Cash Items | 13.20 Cr | 8.04 Cr | 1.80 Cr | 0.32 Cr |
| Deferred Tax | 0.00 | 0.08 Cr | 0.00 | 0.00 |
| Depreciation And Amortization | 16.84 Cr | 10.02 Cr | 1.78 Cr | 0.70 Cr |
| Depreciation | 16.84 Cr | 10.02 Cr | 0.37 Cr | 0.14 Cr |
| Net Foreign Currency Exchange Gain Loss | -2.94 Cr | -0.25 Cr | -1.01 Cr | 0.05 Cr |
| Net Income From Continuing Operations | 70.57 Cr | 24.94 Cr | 12.44 Cr | 1.14 Cr |
| Amortization Cash Flow | — | 3.09 Cr | 1.41 Cr | 0.56 Cr |
| Pension And Employee Benefit Expense | — | -0.03 Cr | -0.01 Cr | 0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Senores Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.